ReviewReviews in medical virology2026
HHV-8 Infection in Solid-Organ Transplant-Pathogenesis, Epidemiology, Clinical Manifestations and Management.
Review in Reviews in medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human herpesvirus-8 (HHV-8) is an oncogenic herpesvirus that poses unique challenges in solid-organ transplantation. Although uncommon, HHV-8-associated diseases including Kaposi sarcoma (KS), multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and the KSHV inflammatory cytokine syndrome (KICS) can lead to significant morbidity, graft loss, and death. The clinical spectrum ranges from indolent cutaneous lesions to fulminant systemic inflammation, yet recognition is often delayed because of nonspecific presentations and the lack of standardized screening or monitoring strategies. Regional differences in HHV-8 seroprevalence and immunosuppressive regimens further complicate prevention and management. This review summarises current understanding of HHV-8 infection in solid-organ transplant recipients, focussing on epidemiology, transmission pathways, pathogenesis, clinical manifestations, diagnostic approaches, and management principles for each major syndrome. It also highlights knowledge gaps, therapeutic challenges, and priorities for research and standardized surveillance to improve outcomes in this rare but important group of transplant-related complications. We propose a risk-stratified donor and recipient screening algorithm and a practical management framework for recipients with HHV-8 PCR positivity but without symptoms, to guide clinical practice in the absence of standardized guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.